Positron emission tomography complete metabolic response as a favorable prognostic predictor in esophageal cancer following neoadjuvant chemotherapy with docetaxel/cisplatin/5-fluorouracil

doi:10.5306/wjco.v12.i4.249

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4913)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-7) series.

Item

Count

PDF

210

WORD

246

HTML

1993

Figures (1-1)

323

Tables (1-7)

506

Sum=3278

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

454

Download

1181

Sum=1635

Apr 24, 2021 (publication date) through Dec 26, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Clin Oncol. Apr 24, 2021; 12(4): 249-261
Published online Apr 24, 2021. doi: 10.5306/wjco.v12.i4.249

Table 1 Patient characteristics

	PET-CMR, n = 22	Non-PET-CMR, n = 36	P value
Age, mean	65.9 (48.0-76.0)	65.0 (47.0-80.0)	0.82
Male/Female	20/2	33/3	0.41
Comorbidity	15	28
Location
Ce	1	4	0.58
Ut	4	3
Mt	10	17
Lt	7	12
Before NAC
cStage
cT
T1	2	0	0.044
T2	6	3
T3	13	32
T4	1	1
cN
N0	5	9	0.27
N1	12	14
N2	4	13
N3	1	0
cM
M0	17	28	0.96
M1	5	8
cStage
I	3	4	0.94
II	4	5
III	10	19
IVA	5	8
IVB	0	0
Primary, SUV_max mean	16.4 ± 6.5	15.7 ± 6.5	0.98
LN+	14 (63.6%)	21 (58.3%)	0.69
After NAC
CT-Stage
T
T1	9	2	0.0058
T2	12	26
T3	1	6
T4	0	2
N
N0	21	21	0.0081
N1	1	8
N2	0	7
N3	0	0
M
M0	22	36	-
M1	0	0
Stage
0	5	0	0.0017
I	4	1
II	12	23
III	1	10
IVA	0	2
IVB	0	0
Down stage	15	17	0.119

Ce: Cervical esophagus; CT: Computed tomography; LN: Lymph node; Lt: Lower thoracic esophagus; Mt: Middle thoracic esophagus; NAC: Neoadjuvant chemotherapy; PET-CMR: Positron emission tomography-complete metabolic response; SUV_max: Maximal standardized uptake value; Ut: Upper thoracic esophagus

Table 2 Surgical outcomes

	PET-CMR, n = 22	Non-PET-CMR, n = 36	P value
Esophagectomy procedures
Subtotal	20	32	0.31
Cervical	1	0
Pharyngeal laryngeal	1	4
LN dissection
Cervical	1	2	0.89
2 fields	5	10
3 fields	16	24
Harvested LN¹	72 ± 7	73 ± 5	0.91
Blood loss in mL¹	559 ± 219	836 ± 540	0.026
OP time in min¹	527 ± 105	580 ± 121	0.092
Curability
R0	22	29	0.027
R1	0	7
Intraoperative complication
Bronchus injury	1	1	0.72
Postoperative complication
All	14	22	0.85
Anastomotic leakage²	1	1	0.72
Anastomotic stenosis²	2	3	0.92
Recurrent nerve palsy²	7	12	0.91
Respiratory²	3	8	0.42
Others²	2	3	0.92
Surgical mortality	0	0	-

¹mean ± SD.

²Clavien-Dindo Classification ≥ 3.

LN: Lymph node; OP: Operation; PET-CMR: Positron emission tomography-complete metabolic response.

Table 3 Pathological findings

	PET-CMR, n = 22	Non-PET-CMR, n = 36	P value
T
T0	9	5	< 0.0001
T1	11	4
T2	1	9
T3	1	12
T4	0	6
N
N0	13	14	0.052
N1	7	7
N2	2	8
N3	0	7
M
M0	20	32	0.81
M1	2	4
Stage
0	9	3	0.033
I	3	8
II	8	8
III	0	10
IVA	2	4
IVB	0	3
Ly+	4	22	0.001
v+	1	15	0.002
Pathological grade
0	0 (0%)	3 (8%)	0.029
1a	4 (18%)	14 (39%)
1b	3 (14%)	6 (17%)
2	6 (27%)	10 (28%)
3	9 (41%)	3 (8%)

Ly: Lymphatic invasion; PET-CMR: Positron emission tomography-complete metabolic response; v: Venous invasion.

Table 4 Accuracy of positron emission tomography complete metabolic response

	TP	FP	TN	FN	Accuracy	Sensitivity	Specificity
T factor	30	4	10	14	69.0%	68.2%	71.4%
N factor	13	2	25	18	65.5%	41.9%	92.6%
T and N	33	3	13	9	72.4%	71.7%	75.0%

FN: False negative; FP: False positive; TN: True negative; TP: True positive.

Table 5 Sites of recurrence

	PET-CMR, n = 5	Non-PET-CMR, n = 17	P value
Local	0	4	0.66
Distant	5	16
Extraregional LN	3	6
Liver	0	5
Bone	1	4
Lung	1	3
Pleura	0	2

LN: Lymph node; PET-CMR: Positron emission tomography-complete metabolic response.

Table 6 Univariable and multivariable analyses of prognostic factors in esophageal cancer

	Relapse-free survival
	Univariate			Multivariate
	RR	95%CI	P value	RR	95%CI	P value
Age	0.982	0.935-1.033	0.468
Male/Female	2.211	0.638-5.920	0.1885
Location, MtLtAe/CeUt	1.230	0.406-3.090	0.689
Tumor grade, other/por	2.612	1.050-6.026	0.040	1.412	0.498-3.785	0.503
pT, 0▪1▪2/3▪4	4.554	1.983-10.770	0.0004	1.195	0.433-3.432	0.734
pN, 0/1▪2▪3	5.287	2.062-16.320	0.0003	3.172	1.074-10.710	0.036
pM, 0/1	2.543	0.726-6.977	0.131
pStage, 0▪1▪2/3▪4	8.655	3.652-22.060	< 0.0001	2.449	0.356-16.800	0.357
pCR (primary tumor), CR (+)/nonCR (-)	5.199	1.501-32.770	0.0063	1.878	0.337-15.060	0.487
CT-PET-T, (-)/(+)	2.561	1.059-7.120	0.0036
CT-PET-N, (-)/(+)	10.810	4.251-28.160	< 0.0001	22.570	4.694-177.800	< 0.0001
CT-PET-CMR, (-)/(+)	2.523	1.034-7.063	0.041

Ae: Abdominal esophagus; Ce: Cervical esophagus; CI: Confidence interval; CR: Complete response; CT-PET-N: Computed tomography-positron emission tomography negative N; CT-PET-T: Computed tomography-positron emission tomography negative T; Lt: Lower thoracic esophagus; Mt: Middle thoracic esophagus; pCR: Pathological complete response; PET-CMR: Positron emission tomography-complete metabolic response; por: Poorly differentiated carcinoma; RR: Relative risk; Ut: Upper thoracic esophagus.

Table 7 Univariable and multivariable analyses of prognostic factors in esophageal cancer

	Overall survival
	Univariate			Multivariate
	RR	95%CI	P value	RR	95%CI	P value
Age	1.036	0.972-1.112	0.285
Male/Female	1.302	0.204-4.683	0.736
Location, MtLtAe/CeUt	1.057	0.242-3.291	0.931
Tumor grade, other/por	1.603	0.499-4.466	0.403
0▪1▪2/3▪4	8.167	2.912-25.340	< 0.0001	1.644	0.430-8.039	0.486
pN, 0/1▪2▪3	5.653	1.803-24.800	0.0021	0.924	0.045-7.556	0.946
pM, 0/1	5.043	1.354-15.690	0.019	1.518	0.302-6.353	0.588
pStage, 0▪1▪2/3▪4	15.52	5.062-58.400	< 0.0001	5.760	0.415-160.800	0.197
pCR (primary tumor), CR (+)/nonCR (-)	3.202	0.887-20.470	0.0793
CT-PET-T, (-)/(+)	3.227	1.106-11.680	0.0313	1.450	0.307-6.866	0.630
CT-PET-N, (-)/(+)	25.270	6.361-168.100	< 0.0001	8.268	1.748-63.630	0.006
CT-PET-CMR, (-)/(+)	2.927	0.996-10.660	0.0510

Citation: Suzuki K, Etoh T, Shibata T, Nishiki K, Fumoto S, Ueda Y, Shiroshita H, Shiraishi N, Inomata M. Positron emission tomography complete metabolic response as a favorable prognostic predictor in esophageal cancer following neoadjuvant chemotherapy with docetaxel/cisplatin/5-fluorouracil. World J Clin Oncol 2021; 12(4): 249-261
URL: https://www.wjgnet.com/2218-4333/full/v12/i4/249.htm
DOI: https://dx.doi.org/10.5306/wjco.v12.i4.249